Condition: Polycystic Kidney, Autosomal Dominant · Sponsor: University of Cologne
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.
This description comes directly from the study's public registry record.
Roman-Ulrich Müller, Prof. · +49221478191005 · STOP-PKD@uk-koeln.de
Philipp Scherrer, MD · +49221478191005 · STOP-PKD@uk-koeln.de
Always discuss trial participation with your own doctor first.
| Vorarlberger Krankenhaus-Betriebsgesellschaft | Feldkirch, Austria | Recruiting |
| Medizinische Universitaet Innsbruck | Innsbruck, Austria | Recruiting |
| Robert Bosch Gesellschaft für Medizinische Forschung mbH | Stuttgart, Baden-Wurttemberg, Germany | Recruiting |
| Klinikum Nürnberg | Nuremberg, Bavaria, Germany | Not Yet Recruiting |
| Universitaetsklinikum Aachen AöR | Aachen, Germany | Recruiting |
| Charite Universitaetsmedizin Berlin KöR | Berlin, Germany | Recruiting |
| Universitätsklinikum Köln | Cologne, Germany | Recruiting |
| Klinikum Dortmund gGmbH | Dortmund, Germany | Recruiting |
| Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR | Dresden, Germany | Recruiting |
| Universitaetsklinikum Duesseldorf AöR | Düsseldorf, Germany | Recruiting |
| Goethe University Frankfurt | Frankfurt, Germany | Recruiting |
| Medical Center - University of Freiburg | Freiburg im Breisgau, Germany | Not Yet Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07280585